<DOC>
	<DOCNO>NCT02046798</DOCNO>
	<brief_summary>This study measure much trial drug enters body long take body remove via feces urine . In addition , different breakdown product single oral dose radio-active ASP3652 identify .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics , Metabolism Excretion Routes ASP3652 Man , After Administration 14C Radio Labeled ASP3652</brief_title>
	<detailed_description>This open-label , one-period , single-dose study 14C label ASP3652 . Screening take place Day 22 Day 2 , subject admit clinic Day -1 . On morning Day 1 , subject receives single oral dose 14C-labeled ASP3652 . Blood , urine feces sample analysis 14C radioactivity collect least 120 h dose . Blood sample analysis ASP3652 metabolites collect 120 h dosing . The subject remain clinic Day 6 ( Day 13 case discharge criterion meet Day 6 ) return End Study Visit ( ESV ) 7 14 day ( early ) discharge .</detailed_description>
	<criteria>Subject white Caucasian origin . Regular defecation pattern ( minimum per day ) . Subject must agree use condom sexual intercourse 3 month dose . In addition use condom , subject must agree practice adequate contraceptive method female sexual partner prevent pregnancy . Known suspected hypersensitivity ASP3652 component formulation use . Donation blood blood product within 3 month prior admission Clinical Unit . Exposure radiation diagnostic reason ( except dental Xrays plain Xrays thorax bony skeleton ( exclude spinal column ) ) , work participation clinical study previous year .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP3652</keyword>
	<keyword>14C radio-labeled</keyword>
	<keyword>Phase 1</keyword>
</DOC>